Personalized Medicine for Gastrointestinal Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1003

Special Issue Editors


E-Mail Website
Guest Editor
1. First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
2. Colorectal Department, Addenbrooke’s Hospital, Cambridge University Hospitals NHS, Cambridge CB2 0QQ, UK
Interests: colorectal surgery; colorectal cancer; IBD
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue on 'Personalized Medicine for Gastrointestinal Diseases'. The goal of precision medicine is to provide a personalized approach for the prevention, diagnosis, prognosis, and treatment of a disease. Gastrointestinal diseases are prevalent and complex conditions that involve a combination of genetic, environmental, infectious, and host-related factors. Gastrointestinal diseases have a significant impact on public health globally, leading to substantial healthcare costs. Understanding their molecular interactions is crucial in unraveling the pathophysiology of these diseases and in developing effective treatments. Recent research has highlighted the importance of the intestinal microbiome and immune factors in the development and progression of gastrointestinal diseases. These insights have revolutionized our understanding of these conditions and paved the way for new therapeutic approaches. Over the past two decades, significant advancements have been made in identifying the molecular mechanisms involved in the development of gastrointestinal diseases, leading to improved treatment options for patients. In recent years, the fields of endoscopy, radiology, and surgery have seen significant advancements due to the rapid development of new techniques. One major contributing factor has been the incorporation of artificial intelligence, which has played a crucial role in driving progress in various aspects of these medical disciplines. Nevertheless, there remain numerous difficult issues to address in the diagnosis and management of gastrointestinal disorders.

This Special Issue aims to compile a diverse selection of papers focused on the pathophysiology, diagnosis, and treatment of gastrointestinal diseases. This includes research on new molecular mechanisms, innovative endoscopic and surgical techniques, differential diagnosis methods, diagnostic models, improvements in diagnostic procedures, advancements in endoscopic and surgical treatments, and the utilization of artificial intelligence in the field of gastrointestinal diseases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Precision medicine for the prevention, prognosis, diagnosis, and differential diagnosis of gastrointestinal diseases.
  • Personalized medicine for the medical treatment of gastrointestinal diseases.
  • Advances in molecular medicine on gastrointestinal diseases.
  • Clinical application of personalized medicine for the diagnosis and treatment of gastrointestinal diseases.
  • Novel techniques in the diagnosis and treatment (e.g., pharmaceutical, interventional, and surgical) of gastrointestinal diseases.

We look forward to receiving your contributions.

Dr. Athanasios Syllaios
Dr. Dimitrios Schizas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • molecular mechanisms
  • gastrointestinal diseases
  • artificial intelligence
  • diagnosis and treatment
  • gastrointestinal cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 1065 KiB  
Systematic Review
Primary Actinomycosis of the Stomach: A Review of the Literature for A Rare Entity
by Afroditi Ziogou, Ilias Giannakodimos, Alexios Giannakodimos, Evangelia Mitakidi, Nikolaos Charalampakis and Petros Ioannou
J. Pers. Med. 2025, 15(3), 116; https://doi.org/10.3390/jpm15030116 - 17 Mar 2025
Viewed by 382
Abstract
Background/Objectives: Primary gastric actinomycosis is extremely rare and only a limited number of cases are published in the literature. Actinomycosis is caused by anaerobic Gram-positive bacteria; these microorganisms are members of the normal human microbiome and occasionally lead to infection, especially in immunocompromised [...] Read more.
Background/Objectives: Primary gastric actinomycosis is extremely rare and only a limited number of cases are published in the literature. Actinomycosis is caused by anaerobic Gram-positive bacteria; these microorganisms are members of the normal human microbiome and occasionally lead to infection, especially in immunocompromised patients or patients subjected to abdominal surgery. Advances in personalized medicine, including tailored antimicrobial therapy based on individual patient profiles, may enhance treatment efficacy and reduce unnecessary interventions. Methods: A review was performed through a literature search of the PubMed/MedLine and Scopus databases. Results: A total of 27 patients were included, 15 males (55.56%) and 12 (44.44%) females, with a mean age of 55.11 ± 17.48 years. Among the included patients, 25.93% had a history of abdominal surgery. Abdominal pain (73.08%), weight loss (40.74%), nausea or vomiting (30.77%) and fever (19.23%) constitute the most commonly reported clinical manifestations. Endoscopy (59.26%), computed tomography (48.15%), ultrasonography (22.22%) and magnetic resonance imaging (11.11%) assisted in indicating the primary lesion. Diagnosis was achieved preoperatively in 66.66% of patients, via endoscopy and biopsy (51.85%) or via cultures (14.81%), while nine cases (33.33%) were diagnosed postoperatively. The therapeutic approaches included antimicrobial administration (32%), surgery (24%) or both (44%). The most widely used antimicrobial was penicillin (77.78%) and the mean duration of antimicrobial treatment was 5.85 months. The protocol for this review was registered in Prospero (ID:CRD42025649532). Conclusions: Due to the divergent clinical presentation of primary gastric actinomycosis, clinicians should be aware of this rare entity in order to establish diagnosis in a timely manner and provide prompt and effective treatment. Full article
(This article belongs to the Special Issue Personalized Medicine for Gastrointestinal Diseases)
Show Figures

Figure 1

Back to TopTop